uniQure N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QURE Nasdaq 2836 www.uniqure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for uniQure N.V.

Lake Street: AMT-130 Could Be Game-Changer For ClearPoint - Jun 22nd, 2025 11:38 pm
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - Jun 11th, 2025 6:00 am
Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint - Jun 4th, 2025 6:55 am
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - Jun 2nd, 2025 5:05 am
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) - May 29th, 2025 5:05 am
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - May 19th, 2025 6:00 am
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? - May 14th, 2025 7:55 am
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - May 10th, 2025 1:04 am
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - May 9th, 2025 6:20 am
UniQure: Q1 Earnings Snapshot - May 9th, 2025 5:18 am
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - May 9th, 2025 5:05 am
uniQure to Announce First Quarter 2025 Financial Results - May 5th, 2025 2:05 pm
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - Apr 29th, 2025 7:10 am
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Apr 21st, 2025 7:54 am
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy - Apr 21st, 2025 6:54 am
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease - Apr 17th, 2025 5:17 am
uniQure Full Year 2024 Earnings: Misses Expectations - Mar 1st, 2025 5:18 am
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Feb 27th, 2025 6:35 am
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - Feb 27th, 2025 5:05 am
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Feb 20th, 2025 3:44 am